MedTrace Logo

A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL

NCT05138458 · Status: SUSPENDED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-11-13

No results posted yet for this study

Summary

This is a Phase 1/2 study to test the safety, tolerability, and efficacy of the investigational agent MT-101 in patients with T cell Lymphoma. MT-101 is made with myeloid cells collected from the patient's blood. The myeloid cells are modified and later infused back into their veins. The modified myeloid cells recognize the tumor cells and are designed to target and kill them.

Conditions

  • Lymphoma, T-Cell, Peripheral
  • Lymphoma, T-Cell, Cutaneous
  • Mycosis Fungoides
  • Adoptive Cellular Immunotherapy
  • Cell Therapy

Interventions

BIOLOGICAL

MT-101

CD5 ATAK cells

OTHER

MT-101 + Conditioning (Lymphodepleting) Chemotherapy

IV administration of fludarabine and cyclophosphamide

Sponsors & Collaborators

  • Myeloid Therapeutics

    lead INDUSTRY

Principal Investigators

  • Michele Gerber, MD, MPH · Myeloid Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-15
Primary Completion
2024-11-30
Completion
2025-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05138458 on ClinicalTrials.gov